Affimed N.V. (0HL9.L)
USD 0.73
(1.12%)
USD 0.73
(1.12%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 8.27 Million EUR | -79.99% |
| 2022 | 41.35 Million EUR | 2.45% |
| 2021 | 40.36 Million EUR | 42.33% |
| 2020 | 28.36 Million EUR | 32.58% |
| 2019 | 21.39 Million EUR | -9.88% |
| 2018 | 23.73 Million EUR | 1080.85% |
| 2017 | 2.01 Million EUR | -68.17% |
| 2016 | 6.31 Million EUR | -16.5% |
| 2015 | 7.56 Million EUR | 123.6% |
| 2014 | 3.38 Million EUR | -33.52% |
| 2013 | 5.08 Million EUR | 333.67% |
| 2012 | 1.17 Million EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 155 Thousand EUR | -62.47% |
| 2024 Q2 | 154 Thousand EUR | -0.65% |
| 2023 Q1 | 4.51 Million EUR | -59.58% |
| 2023 FY | 8.27 Million EUR | -79.99% |
| 2023 Q2 | 1.39 Million EUR | -69.18% |
| 2023 Q4 | 413 Thousand EUR | -78.95% |
| 2023 Q3 | 1.96 Million EUR | 41.15% |
| 2022 FY | 41.35 Million EUR | 2.45% |
| 2022 Q3 | 14.88 Million EUR | 103.92% |
| 2022 Q2 | 7.3 Million EUR | -8.81% |
| 2022 Q1 | 8 Million EUR | -22.56% |
| 2022 Q4 | 11.15 Million EUR | -25.05% |
| 2021 FY | 40.36 Million EUR | 42.33% |
| 2021 Q1 | 11.65 Million EUR | 19.63% |
| 2021 Q2 | 9.7 Million EUR | -16.74% |
| 2021 Q3 | 8.66 Million EUR | -10.77% |
| 2021 Q4 | 10.33 Million EUR | 19.35% |
| 2020 Q4 | 9.74 Million EUR | -7.58% |
| 2020 FY | 28.36 Million EUR | 32.58% |
| 2020 Q3 | 10.54 Million EUR | 259.41% |
| 2020 Q2 | 2.93 Million EUR | -42.86% |
| 2020 Q1 | 5.13 Million EUR | 30.76% |
| 2019 Q3 | 2.1 Million EUR | -47.53% |
| 2019 Q2 | 4 Million EUR | -64.7% |
| 2019 FY | 21.39 Million EUR | -9.88% |
| 2019 Q1 | 11.35 Million EUR | -50.09% |
| 2019 Q4 | 3.92 Million EUR | 86.73% |
| 2018 Q4 | 22.74 Million EUR | 7333.66% |
| 2018 Q1 | 532 Thousand EUR | -16.35% |
| 2018 FY | 23.73 Million EUR | 1080.85% |
| 2018 Q3 | 306 Thousand EUR | 104.0% |
| 2018 Q2 | 150 Thousand EUR | -71.8% |
| 2017 Q2 | 508 Thousand EUR | 27.32% |
| 2017 Q3 | 467 Thousand EUR | -8.07% |
| 2017 Q4 | 636 Thousand EUR | 36.19% |
| 2017 Q1 | 399 Thousand EUR | -70.9% |
| 2017 FY | 2.01 Million EUR | -68.17% |
| 2016 Q2 | 2.06 Million EUR | 6.87% |
| 2016 FY | 6.31 Million EUR | -16.5% |
| 2016 Q1 | 1.93 Million EUR | 16.7% |
| 2016 Q4 | 1.37 Million EUR | 46.16% |
| 2016 Q3 | 938 Thousand EUR | -54.66% |
| 2015 Q3 | 1.15 Million EUR | -47.74% |
| 2015 Q4 | 1.65 Million EUR | 43.64% |
| 2015 Q2 | 2.21 Million EUR | -12.92% |
| 2015 Q1 | 2.53 Million EUR | 3033.33% |
| 2015 FY | 7.56 Million EUR | 123.6% |
| 2014 FY | 3.38 Million EUR | -33.52% |
| 2014 Q1 | 722 Thousand EUR | -84.39% |
| 2014 Q2 | 687 Thousand EUR | -4.85% |
| 2014 Q3 | 1.89 Million EUR | 175.4% |
| 2014 Q4 | 81 Thousand EUR | -95.72% |
| 2013 Q1 | 70 Thousand EUR | 0.0% |
| 2013 Q4 | 4.62 Million EUR | 2321.47% |
| 2013 Q2 | 201 Thousand EUR | 187.14% |
| 2013 FY | 5.08 Million EUR | 333.67% |
| 2013 Q3 | 191 Thousand EUR | -4.98% |
| 2012 FY | 1.17 Million EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 15.22 Billion USD | 99.946% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | 52.22% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | 2743.77% |
| Cara Therapeutics, Inc. | 14.79 Million USD | 44.065% |
| uniQure N.V. | 2.21 Million USD | -273.589% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | 97.714% |
| bluebird bio, Inc. | -4.03 Million USD | 305.335% |
| Imunon, Inc. | -720 Thousand USD | 1249.298% |
| Dynavax Technologies Corporation | 182.11 Million USD | 95.456% |
| Editas Medicine, Inc. | -99.52 Million USD | 108.314% |
| Illumina, Inc. | 2.74 Billion USD | 99.698% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | 186.504% |
| IQVIA Holdings Inc. | 5.23 Billion USD | 99.842% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 99.619% |
| Myriad Genetics, Inc. | 476.4 Million USD | 98.263% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 99.552% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | 99.243% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 98.42% |
| Verastem, Inc. | -62 Thousand USD | 13446.774% |
| Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 99.969% |
| Waters Corporation | 1.76 Billion USD | 99.53% |
| Biogen Inc. | 7.3 Billion USD | 99.887% |
| Nektar Therapeutics | 53.47 Million USD | 84.526% |
| Perrigo Company plc | 1.68 Billion USD | 99.508% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 126.55% |
| Heron Therapeutics, Inc. | 10.04 Million USD | 17.596% |
| Unity Biotechnology, Inc. | -19.69 Million USD | 142.007% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | 99.565% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | 118.257% |
| Evolus, Inc. | 140.52 Million USD | 94.111% |
| Adicet Bio, Inc. | -6.09 Million USD | 235.7% |
| Aclaris Therapeutics, Inc. | -85.21 Million USD | 109.711% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 99.927% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | 88.675% |
| FibroGen, Inc. | 128.9 Million USD | 93.58% |
| Agilent Technologies, Inc. | 3.46 Billion USD | 99.761% |
| OPKO Health, Inc. | 318.12 Million USD | 97.399% |
| Homology Medicines, Inc. | -7.22 Million USD | 214.469% |
| Geron Corporation | -123.5 Million USD | 106.7% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | 99.455% |
| Exelixis, Inc. | 1.75 Billion USD | 99.529% |
| Viking Therapeutics, Inc. | -292 Thousand USD | 2933.904% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 102.075% |
| Zoetis Inc. | 5.83 Billion USD | 99.858% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | 96.616% |
| Abeona Therapeutics Inc. | 302 Thousand USD | -2640.066% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 99.904% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 2831.023% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | 98.937% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | 98.261% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | 98.701% |
| Blueprint Medicines Corporation | 236.58 Million USD | 96.502% |
| Insmed Incorporated | 239.63 Million USD | 96.547% |
| TG Therapeutics, Inc. | 219.1 Million USD | 96.223% |
| Incyte Corporation | 3.44 Billion USD | 99.759% |
| Emergent BioSolutions Inc. | 343.9 Million USD | 97.594% |